Massive human rivaroxaban overdose
- 1 January 2014
- journal article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 112 (10) , 834-836
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation testsThrombosis Research, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitorThrombosis and Haemostasis, 2010
- Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assayThrombosis and Haemostasis, 2010
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip ArthroplastyNew England Journal of Medicine, 2008
- Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in healthy subjectsInt. Journal of Clinical Pharmacology and Therapeutics, 2007
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClinical Pharmacology & Therapeutics, 2005
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005
- Importance of factor Xa in determining the procoagulant activity of whole-blood clots.Journal of Clinical Investigation, 1993